Furthermore, tumours bearing high levels of oncogene-induced DNA damage response (DDR), such as MYC driven murine lymphoma (Eμ-Myc) and human B-cell lymphomas, are sensitive to therapeutic targeting of DNA-dependent Protein Kinase (DNA-PK) and ATM/ ATR [67–69]. Here, PRKDC is linked to B-cell non-Hodgkin lymphoma.